BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31191661)

  • 1. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids.
    Hennig A; Wolf L; Jahnke B; Polster H; Seidlitz T; Werner K; Aust DE; Hampe J; Distler M; Weitz J; Stange DE; Welsch T
    Stem Cells Int; 2019; 2019():1024614. PubMed ID: 31191661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
    Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
    J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An organoid model to assay the role of CFTR in the human epididymis epithelium.
    Leir SH; Yin S; Kerschner JL; Xia S; Ahmadi S; Bear C; Harris A
    Cell Tissue Res; 2020 Aug; 381(2):327-336. PubMed ID: 32377875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
    Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
    BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells.
    Choi JI; Jang SI; Hong J; Kim CH; Kwon SS; Park JS; Lim JB
    Cancer Lett; 2021 Feb; 498():42-53. PubMed ID: 33188841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
    Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
    Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
    Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
    Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
    Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
    Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
    Rittmann MC; Hussung S; Braun LM; Klar RFU; Biesel EA; Fichtner-Feigl S; Fritsch R; Wittel UA; Ruess DA
    Sci Rep; 2021 Apr; 11(1):7499. PubMed ID: 33820913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models.
    Hoare O; Fraunhoffer N; Elkaoutari A; Gayet O; Bigonnet M; Roques J; Nicolle R; McGuckin C; Forraz N; Sohier E; Tonon L; Wajda P; Boyault S; Attignon V; Tabone-Eglinger S; Barbier S; Mignard C; Duchamp O; Iovanna J; Dusetti NJ
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069519
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-cell transcriptome profiling of primary tumors and paired organoids of pancreatobiliary cancer.
    Chen K; Ma Y; Zhong X; Lan J; Long D; Tian X; Yang Y; Yang Y
    Cancer Lett; 2024 Feb; 582():216586. PubMed ID: 38081505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity.
    Zomer-van Ommen DD; de Poel E; Kruisselbrink E; Oppelaar H; Vonk AM; Janssens HM; van der Ent CK; Hagemeijer MC; Beekman JM
    J Cyst Fibros; 2018 May; 17(3):316-324. PubMed ID: 29544685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
    Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression.
    Seino T; Kawasaki S; Shimokawa M; Tamagawa H; Toshimitsu K; Fujii M; Ohta Y; Matano M; Nanki K; Kawasaki K; Takahashi S; Sugimoto S; Iwasaki E; Takagi J; Itoi T; Kitago M; Kitagawa Y; Kanai T; Sato T
    Cell Stem Cell; 2018 Mar; 22(3):454-467.e6. PubMed ID: 29337182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.
    Matsumoto K; Fujimori N; Ichihara K; Takeno A; Murakami M; Ohno A; Kakehashi S; Teramatsu K; Ueda K; Nakata K; Sugahara O; Yamamoto T; Matsumoto A; Nakayama KI; Oda Y; Nakamura M; Ogawa Y
    J Gastroenterol; 2024 Apr; ():. PubMed ID: 38684511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.
    Vijftigschild LA; Berkers G; Dekkers JF; Zomer-van Ommen DD; Matthes E; Kruisselbrink E; Vonk A; Hensen CE; Heida-Michel S; Geerdink M; Janssens HM; van de Graaf EA; Bronsveld I; de Winter-de Groot KM; Majoor CJ; Heijerman HG; de Jonge HR; Hanrahan JW; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Sep; 48(3):768-79. PubMed ID: 27471203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.